CY1123460T1 - Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης - Google Patents
Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχηςInfo
- Publication number
- CY1123460T1 CY1123460T1 CY20201100789T CY201100789T CY1123460T1 CY 1123460 T1 CY1123460 T1 CY 1123460T1 CY 20201100789 T CY20201100789 T CY 20201100789T CY 201100789 T CY201100789 T CY 201100789T CY 1123460 T1 CY1123460 T1 CY 1123460T1
- Authority
- CY
- Cyprus
- Prior art keywords
- clemizole
- pharmaceutically acceptable
- acceptable salt
- methods
- treating
- Prior art date
Links
- 206010015037 epilepsy Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- CJXAEXPPLWQRFR-UHFFFAOYSA-N clemizole Chemical compound C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2N=C1CN1CCCC1 CJXAEXPPLWQRFR-UHFFFAOYSA-N 0.000 abstract 8
- 229950002020 clemizole Drugs 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Στο παρόν παρέχονται, μεταξύ άλλων, μέθοδοι για τη θεραπεία των επιληπτικών διαταραχών χρησιμοποιώντας κλεμιζόλη, ανάλογο κλεμιζόλης ή ένα φαρμακευτικά αποδεκτό άλας αυτής. Σε μία άποψη, η μέθοδος περιλαμβάνει τη χορήγηση σε ένα άτομο που χρήζει αυτής μιας θεραπευτικώς αποτελεσματικής ποσότητας κλεμιζόλης, αναλόγου κλεμιζόλης ή φαρμακευτικά αποδεκτού άλατος αυτής. Σε μια άλλη άποψη, η μέθοδος η μέθοδος περιλαμβάνει τη χορήγηση σε ένα άτομο που χρήζει αυτής μιας φαρμακευτικής σύνθεσης που περιέχει μια θεραπευτικώς αποτελεσματική ποσότητα κλεμιζόλης, αναλόγου κλεμιζόλης ή φαρμακευτικά αποδεκτού άλατος αυτής. Σε μια άποψη, παρέχεται μια φαρμακευτική σύνθεση που περιέχει κλεμιζόλη, ανάλογο κλεμιζόλης ή φαρμακευτικά αποδεκτό άλας αυτής για χρήση στη θεραπεία μιας επιληπτικής διαταραχής.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361867397P | 2013-08-19 | 2013-08-19 | |
PCT/US2014/051731 WO2015026849A1 (en) | 2013-08-19 | 2014-08-19 | Compounds and methods for treating an epileptic disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1123460T1 true CY1123460T1 (el) | 2022-03-24 |
Family
ID=52484102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100789T CY1123460T1 (el) | 2013-08-19 | 2020-08-24 | Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης |
Country Status (13)
Country | Link |
---|---|
US (5) | US9925172B2 (el) |
EP (2) | EP3636264A1 (el) |
CY (1) | CY1123460T1 (el) |
DK (1) | DK3035926T3 (el) |
ES (1) | ES2813450T3 (el) |
HK (1) | HK1225984A1 (el) |
HR (1) | HRP20201302T1 (el) |
HU (1) | HUE053282T2 (el) |
LT (1) | LT3035926T (el) |
PT (1) | PT3035926T (el) |
RS (1) | RS61038B1 (el) |
SI (1) | SI3035926T1 (el) |
WO (1) | WO2015026849A1 (el) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
ES2813450T3 (es) | 2013-08-19 | 2021-03-23 | Univ California | Compuestos y métodos para tratar un trastorno epiléptico |
EA201992474A3 (ru) | 2015-02-25 | 2020-05-31 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа | Агонисты 5ht для лечения нарушений |
KR20180054584A (ko) * | 2015-08-24 | 2018-05-24 | 조게닉스 인터내셔널 리미티드 | 펜플루라민을 사용하여 레녹스-가스토 증후군을 치료하는 방법 |
US11124550B2 (en) * | 2015-12-09 | 2021-09-21 | The University Of Queensland | Proteinaceous molecules and methods of use |
EP4293009A3 (en) | 2015-12-22 | 2024-02-21 | Zogenix International Limited | Fenfluramine compositions and methods of preparing the same |
CA3007673A1 (en) | 2015-12-22 | 2017-06-29 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
US20180055789A1 (en) | 2016-08-24 | 2018-03-01 | Zogenix International Limited | Formulation for inhibiting formation of 5-ht2b agonists and methods of using same |
WO2018064498A1 (en) * | 2016-09-30 | 2018-04-05 | Pairnomix, Llc | Methods of treating epilepsy and related neurological conditions |
US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
JP7105797B2 (ja) | 2016-11-28 | 2022-07-25 | プラクシス プレシジョン メディシンズ, インコーポレイテッド | 化合物及びその使用方法 |
WO2018098500A1 (en) * | 2016-11-28 | 2018-05-31 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
WO2018148745A1 (en) | 2017-02-13 | 2018-08-16 | Praxis Precision Medicines , Inc. | Compounds and their methods of use |
WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11351229B2 (en) | 2017-04-17 | 2022-06-07 | Baylor College Of Medicine | Combination therapies for treating infantile spasms and other treatment resistant epilepsies |
CA3061932A1 (en) * | 2017-05-16 | 2018-11-22 | Evogen, Inc. | Biomarkers and methods for detection of seizures and epilepsy |
WO2018231745A1 (en) | 2017-06-14 | 2018-12-20 | Trevena, Inc. | Compounds for modulating s1p1 activity and methods of using the same |
WO2019035951A1 (en) | 2017-08-15 | 2019-02-21 | Praxis Precision Medicines, Inc. | COMPOUNDS AND THEIR METHODS OF USE |
US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
US20190091174A1 (en) * | 2017-09-26 | 2019-03-28 | Zogenix International Limited | Method of reducing seizure type experienced by a dravet patient |
CA3097335A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
AU2019278814A1 (en) | 2018-05-30 | 2020-12-17 | Praxis Precision Medicines, Inc. | Ion channel modulators |
EP3806835A1 (en) | 2018-06-14 | 2021-04-21 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
CA3149989A1 (en) * | 2019-09-05 | 2021-03-11 | Mark A. DEMITRACK | Methods of treating epilepsy using the same |
JP2023502123A (ja) | 2019-11-19 | 2023-01-20 | トレベナ・インコーポレイテッド | S1p1モジュレーター化合物及び化合物を調製する方法 |
US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
WO2023009228A1 (en) * | 2021-07-30 | 2023-02-02 | Epygenix Therapeutics, Inc. | Clemizole formulation |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2436883C2 (de) | 1974-07-29 | 1985-08-22 | Schering AG, 1000 Berlin und 4709 Bergkamen | Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
JO1410B1 (en) * | 1984-11-03 | 1986-11-30 | سميث كلاين اند فرينش لابوراتوريز ليمتد | Vehicles |
FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US7326536B2 (en) | 2001-05-03 | 2008-02-05 | Eli Lilly And Company | Agents for treatment of HCV and methods of use |
US6559293B1 (en) * | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
WO2005032329A2 (en) | 2003-08-22 | 2005-04-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for identifying anti-hcv agents |
KR20080111015A (ko) * | 2006-03-31 | 2008-12-22 | 아스트라제네카 아베 | 비시클릭 벤즈이미다졸 화합물 및 대사성 글루타메이트 수용체 증강체로서 이들의 용도 |
US8642351B2 (en) | 2006-09-20 | 2014-02-04 | Waters Technologies Corporation | Apparatus and methods of fluid chromatography |
WO2008122932A1 (en) | 2007-04-06 | 2008-10-16 | Koninklijke Philips Electronics N.V. | Air pollution sensor system |
WO2008138123A1 (en) * | 2007-05-09 | 2008-11-20 | Thomas David Y | Screening assay to identify correctors of protein trafficking defects |
US7897636B2 (en) * | 2007-08-08 | 2011-03-01 | Janssen Pharmaceutica Nv | Sulfamide derivative useful for the treatment of epilepsy |
WO2010107742A2 (en) | 2009-03-18 | 2010-09-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions of treating a flaviviridae family viral infection |
JP5715820B2 (ja) | 2007-09-18 | 2015-05-13 | スタンフォード ユニバーシティー | フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物 |
KR100925176B1 (ko) | 2007-09-21 | 2009-11-05 | 한국전자통신연구원 | 지리 정보를 이용한 네트워크 상태 표시장치 및 방법 |
WO2010039195A2 (en) | 2008-09-23 | 2010-04-08 | The Board Of Trustees Of The Leland Stanford Junior University | Screening for inhibitors of hcv amphipathic helix (ah) function |
EP2408449A4 (en) | 2009-03-18 | 2012-08-08 | Univ Leland Stanford Junior | METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS |
WO2011049988A2 (en) | 2009-10-20 | 2011-04-28 | Eiger Biopharmaceuticals, Inc. | Indazoles to treat flaviviridae virus infection |
WO2012149472A2 (en) * | 2011-04-27 | 2012-11-01 | Ignite Institute For Individualized Health | Methods, compositions, and kits for treating and preventing neurological conditions |
EP2797896A1 (en) * | 2011-12-28 | 2014-11-05 | Allergan, Inc. | Benzimidazole derivatives as selective blockers of persistent sodium current |
ES2813450T3 (es) | 2013-08-19 | 2021-03-23 | Univ California | Compuestos y métodos para tratar un trastorno epiléptico |
-
2014
- 2014-08-19 ES ES14838223T patent/ES2813450T3/es active Active
- 2014-08-19 RS RS20201007A patent/RS61038B1/sr unknown
- 2014-08-19 PT PT148382237T patent/PT3035926T/pt unknown
- 2014-08-19 WO PCT/US2014/051731 patent/WO2015026849A1/en active Application Filing
- 2014-08-19 EP EP19210789.4A patent/EP3636264A1/en active Pending
- 2014-08-19 SI SI201431639T patent/SI3035926T1/sl unknown
- 2014-08-19 EP EP14838223.7A patent/EP3035926B1/en active Active
- 2014-08-19 HU HUE14838223A patent/HUE053282T2/hu unknown
- 2014-08-19 DK DK14838223.7T patent/DK3035926T3/da active
- 2014-08-19 LT LTEP14838223.7T patent/LT3035926T/lt unknown
-
2016
- 2016-02-18 US US15/047,254 patent/US9925172B2/en active Active
- 2016-12-19 HK HK16114411A patent/HK1225984A1/zh unknown
-
2018
- 2018-02-08 US US15/892,204 patent/US11684609B2/en active Active
- 2018-12-07 US US16/213,896 patent/US10695325B2/en active Active
-
2020
- 2020-04-30 US US16/864,014 patent/US11291653B2/en active Active
- 2020-08-20 HR HRP20201302TT patent/HRP20201302T1/hr unknown
- 2020-08-24 CY CY20201100789T patent/CY1123460T1/el unknown
-
2023
- 2023-06-26 US US18/341,626 patent/US20230372304A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
HK1225984A1 (zh) | 2017-09-22 |
US20200323825A1 (en) | 2020-10-15 |
DK3035926T3 (da) | 2020-08-31 |
EP3035926A4 (en) | 2017-01-11 |
US10695325B2 (en) | 2020-06-30 |
PT3035926T (pt) | 2020-09-01 |
SI3035926T1 (sl) | 2020-11-30 |
WO2015026849A1 (en) | 2015-02-26 |
ES2813450T3 (es) | 2021-03-23 |
US9925172B2 (en) | 2018-03-27 |
RS61038B1 (sr) | 2020-12-31 |
LT3035926T (lt) | 2020-11-25 |
US20230372304A1 (en) | 2023-11-23 |
HRP20201302T1 (hr) | 2021-02-05 |
US20190167642A1 (en) | 2019-06-06 |
HUE053282T2 (hu) | 2021-06-28 |
ES2813450T8 (es) | 2021-03-31 |
US20160235718A1 (en) | 2016-08-18 |
EP3035926A1 (en) | 2016-06-29 |
US11684609B2 (en) | 2023-06-27 |
EP3636264A1 (en) | 2020-04-15 |
US20180235937A1 (en) | 2018-08-23 |
US11291653B2 (en) | 2022-04-05 |
EP3035926B1 (en) | 2020-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123460T1 (el) | Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης | |
CY1122671T1 (el) | Θεραπευτικως δραστικες ενωσεις και οι μεθοδοι χρησεις αυτων | |
CY1120506T1 (el) | Θεραπευτικα δραστικες ενωσεις και μεθοδοι χρησης αυτων | |
EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
RU2018145985A (ru) | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений | |
EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
CY1121710T1 (el) | Παρεμβασεις με βαση την αγγειοποιητινη για τη θεραπεια της εγκεφαλικης ελονοσιας | |
BR112015022197A2 (pt) | tratamento de cataplexia | |
EA201491391A1 (ru) | Терапевтически активные соединения и способы их применения | |
EA201690044A1 (ru) | Модуляторы ядерного транспорта и их применение | |
PH12017500493A1 (en) | Combination therapy | |
EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
CL2017002242A1 (es) | Método para tratar un tumor cerebral | |
EA202090098A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
UY33863A (es) | Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer | |
EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
EA201692392A1 (ru) | Новая лекарственная форма мелоксикама | |
EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
AR094241A1 (es) | Ciclesonida para el tratamiento de la enfermedad de las vias respiratorias en caballos | |
EA201692155A1 (ru) | МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение |